Evidence map›Paper›PMID 38094610›Full record

ArticleFrontiers in oncology2023

Case Report: Remarkable breakthrough: successful treatment of a rare intracranial mesenchymal, FET::CREB fusion-positive tumor treated with patient-tailored multimodal therapy.

Federica D'Antonio, Sabrina Rossi, Isabella Giovannoni, Rita Alaggio, Andrea Carai, Giuseppe M Milano, Antonella Cacchione, Alessandra Cancellieri, Marco Gessi, Manila Antonelli and 4 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Non-Meningothelial Mesenchymal Tumor of the Central Nervous System: Case Report and Literature Review.Neuropathology : official journal of the Japanese Society of Neuropathology · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Federica D'AntonioDepartment of Experimental Medicine, Faculty of Medicine and Dentistry, Sapienza University of Rome, Rome, Italy.
Sabrina RossiDepartment of Pathology, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.
Isabella GiovannoniDepartment of Pathology, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.
Rita AlaggioDepartment of Pathology, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.
Andrea CaraiUnit of Neurorehabilitation, Department of Intensive Neurorehabilitation and Robotics, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.
Giuseppe M MilanoDepartment of Oncohematology, Hematopoietic Transplantation, and Cell Therapy, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.
Antonella CacchioneDepartment of Oncohematology, Hematopoietic Transplantation, and Cell Therapy, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.
Alessandra CancellieriInstitute of General Pathology, Agostino Gemelli University Polyclinic (IRCCS), Rome, Italy.
Marco GessiInstitute of General Pathology, Agostino Gemelli University Polyclinic (IRCCS), Rome, Italy.
Manila AntonelliDepartment of Radiological, Oncological, and Pathological Anatomy Sciences, Faculty of Medicine and Dentistry, Sapienza University of Rome, Rome, Italy.
Giovanna S ColafatiDepartment of Diagnostic Imaging, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.
Giacomina MegaroInstitute of General Pathology, Agostino Gemelli University Polyclinic (IRCCS), Rome, Italy.
Sabina VennariniRadiotherapy Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Angela MastronuzziDepartment of Oncohematology, Hematopoietic Transplantation, and Cell Therapy, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.
Bambino Gesù Children's Hospital · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITSapienza University of Rome · ITAgostino Gemelli University Polyclinic · ITFondazione IRCCS Istituto Nazionale dei Tumori · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Intracranial mesenchymal tumors are a rare type of neoplasm (0.3% of all soft tissue tumors) characterized by a fusion of a Case description: This case describes a 27-year-old woman with unconventional extracranial metastatic sites of myxoid intracranial mesenchymal tumor Conclusions: Our case sheds light on the importance of precision medicine and tailored therapy to explore new treatment opportunities for rare or unknown tumor entities.

Indexed as

challenging diagnosisFET::CREB gene fusionimmunotherapyintracranial mesenchymal tumormolecular analysismultimodal tailored therapyrare cancers

Identifiers

PMID38094610
PMCPMC10716272
OpenAlexW4389150428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.